Takeda Pharmaceutical Company Limited Overview
Company Headquarters: Japan
Founded: 1925
Workforce: ~ 47,347
Company Working: Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs, and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases, and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
Strategy
The company entered into strategic agreements to improve its market presence and operational performance. Such focus on strengthening its core business operations could provide the company with various new opportunities. In April 2021, the company announced to extend its partnership with Centogene N.V. to diagnose patients with certain genetic disorders. In April 2021, the company and TriNetX entered into an agreement to accelerate the delivery of transformative therapies to patients. In May 2021, the company and Aptamer Group signed an agreement to assess their Optimer technology with a new target class to evaluate the feasibility of working with their drug compounds. In July 2021, the company entered into an additional agreement with Moderna and the Government of Japan’s Ministry of Health, Labour and Welfare to import and distribute Moderna’s mRNA COVID-19 vaccine in Japan. In July 2021, the company entered into a collaboration with Frazier Healthcare Partners to launch HilleVax, Inc to develop and commercialize Takeda’s norovirus vaccine candidate. In September 2021, the company and Pneuma Systems entered into a collaboration to improve patient experience. In September 2021, the company entered into a licensing agreement with Mirum Pharmaceuticals for the development and commercialization of maralixibat in Japan for Alagille syndrome. In October 2021, the company and Immusoft entered into a collaboration to develop cell therapies for rare neurometabolic disorders. In October 2021, the company entered a research collaboration and license agreement with Poseida Therapeutics to develop non-viral in vivo gene therapy programmes. In November 2021, the company and Denali Therapeutics Inc exercised an option to co-develop and co-commercialize DNL593. In December 2021, the company in partnership with National MPS Society, Luna, and Genetic Alliance launched a digital drug discovery community to advance the understanding of and develop therapeutic interventions for patients with Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome. In February 2022, the company and Code Biotherapeutics, Inc announced a collaboration and option agreement to leverage Code Bio’s proprietary targeted 3DNA non-viral genetic medicine delivery platform to design and develop gene therapies for rare disease indications.
